Corrigendum

This article refers to:

Dendrimer Pharmacokinetics: The Effect of Size, Structure and Surface Characteristics on ADME Properties

In the Review by Lisa M Kaminskas, Ben J Boyd and Christopher JH Porter, entitled Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties (Nanomedicine 6[6], 1063–1084 [2011]; www.tandfonline.com/doi/pdf/10.2217/nnm.11.173), Figure 6 and the figure legend were incorrectly published as:

Figure 6. Correlation between molecular weight and plasma clearance for a series of PEGylated dendrimers with different scaffolds.

(A) The plasma clearance of published PEGylated dendrimers. Symbols in the left panel represent half-PEGylated polyester bow-tie dendrimers (triangle [22]), fully PEGylated triazine dendrimers (light colored circle [21]), fully PEGylated polylysine dendrimers (black circle [16]), 50% PEGylated and 50% methotrexate polylysine dendrimers (square [30]), 50% PEGylated and 50% uncapped, hydrazone linker or hydrazone linker plus doxorubicin polylysine dendrimers (inverted triangle [86]), partly PEGylated PAMAM dendrimers containing a PAMAM or phosphazine core labeled with GO3A-Gd (cross [35] [Margerum L, Unpublished Data]; data for three constructs were based on n = 1 rat only) partly PEGylated polylysine dendrimers labeled with DTPA-In (diamond [34]) and partly PEGylated PAMAM dendrimers labeled with DTPA-In (star [33]). Closed symbols represent dendrimers that were radiolabeled with tritium or iodine. (B) Clearance data for dendrimers that were smaller than 80 kDa (closed symbols) and that were not labeled with In were consistent with a sigmoidal relationship (GraphPad Prism using the equation Y = bottom + (top - bottom)/(1 + 10^(log IC50-X) × HillSlope), where the lower limit was restricted to be >1.5 and the upper limit was restricted to <1000 and IC50 was restricted to be equal to 20 kDa [B]). Gray symbols in (B) represent outlying points that included an 11 kDa triazine dendrimer [21] and a G₁ polyester dendrimer conjugated with two PEG20000 chains [22]. Clearance was back calculated from published terminal half-life and AUC values for [22] and [21]. Pharmacokinetic parameters were estimated from plasma concentration–time profiles for [33–35] [Margerum L, Unpublished Data]. Clearance data were normalized for bodyweight based on the published average weight of animals used or the average weight of animals at the quoted age range for each species.

The correct figure is shown below:

Figure 6. Correlation between molecular weight and plasma clearance for a series of PEGylated dendrimers with different scaffolds.

(A) The plasma clearance of published PEGylated dendrimers. Symbols in the left panel represent half-PEGylated polyester bow-tie dendrimers (triangle [22]), fully PEGylated triazine dendrimers (black circle [21]), fully PEGylated polylysine dendrimers (light colored circle [16]), 50% PEGylated and 50% methotrexate polylysine dendrimers (square [30]), 50% PEGylated and 50% uncapped, hydrazone linker or hydrazone linker plus doxorubicin polylysine dendrimers (inverted triangle [86]), partly PEGylated PAMAM dendrimers containing a PAMAM or phosphazine core labeled with GO3A-Gd (cross [35] [Margerum L, Unpublished Data]; data for three constructs were based on n = 1 rat only) partly PEGylated polylysine dendrimers labeled with DTPA-In (diamond [34]) and partly PEGylated PAMAM dendrimers labeled with DTPA-In (star [33]). Closed symbols represent dendrimers that were radiolabeled with tritium or iodine. (B) Clearance data for dendrimers that were smaller than 80 kDa (closed symbols) and that were not labeled with In or Gd fitted a sigmoidal relationship (GraphPad Prism using the equation Y = bottom + (top - bottom)/(1 + 10^(log IC50-X) × HillSlope), where the lower limit was restricted to be >1.5 and the upper limit was restricted to <1000 and IC50 was restricted to be equal to 20 kDa [B]). Gray symbols in (B) represent outlying points that included an 11 kDa triazine dendrimer [21] and a G₁ polyester dendrimer conjugated with two PEG20000 chains [22]. Clearance was back calculated from published terminal half-life and AUC values for [22] and [21]. Pharmacokinetic parameters were estimated from plasma concentration–time profiles for [33–35] [Margerum L, Unpublished Data]. Clearance data were normalized for bodyweight based on the published average weight of animals used or the average weight of animals at the quoted age range for each species.

The authors and editors of Nanomedicine would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.